June 24, 2021
3 min watch
Save
VIDEO: CheckMate 816 shows efficacy, safety of neoadjuvant immunotherapy prior to surgery
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Nathan A. Pennell, MD, PhD, spoke with Healio about phase 3 findings from the CheckMate 816 trial presented at the virtual ASCO Annual Meeting.
“There is a perception among surgeons that giving people immunotherapy before surgery may make surgical resection more complicated, patients may have adverse events that lead to not being able to get surgery and so there’s a lot of concern about this,” Pennell, medical oncologist at the Cleveland Clinic and associate professor medical oncology at the Cleveland Clinic Lerner College, said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview; Spicer J, et al. Abstract 8503. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Disclosures:
Disclosure: Pennell reports serving in a consulting or advisory role for Bristol Myer Squibb, Genentech and Janssen.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.